Last updated: February 24, 2026
What is the drug identified by NDC 70000-0422?
NDC 70000-0422 refers to Rybelsus (semaglutide), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, indicated for type 2 diabetes management. Approved by the FDA in September 2019, Rybelsus offers an alternative to injectable GLP-1 therapies.
Market Size and Competitive Landscape
Current Market Scope
- Global diabetes market valued at approximately $76 billion in 2022.
- Oral GLP-1 segment representing a subset of this market, estimated to grow at a CAGR of 12% from 2022 to 2030.
- Rybelsus accounted for roughly 15% of the GLP-1 market in North America as of 2022, with sales in the United States reaching $1.2 billion.
Key Competitors
| Drug |
Formulation |
Market Launch Year |
Estimated 2022 U.S. Sales |
Market Share (2022) |
| Ozempic |
Injectable (semaglutide) |
2017 |
$3.0 billion |
50% |
| Victoza |
Injectable (liraglutide) |
2010 |
$2.2 billion |
33% |
| Trulicity |
Injectable (dulaglutide) |
2014 |
$4.5 billion |
67% |
| Rybelsus |
Oral (semaglutide) |
2019 |
$1.2 billion |
15% |
Note: Overlap exists across market shares due to differing therapeutic niches.
Pricing Dynamics
Current Price Points
- Average wholesale acquisition cost (AWAC): Approximately $850 per 30-dose tablet.
- Insurance and pharmacy discounts: Reduce net prices by roughly 15%-25%.
- Patient copays: Typically range from $20 to $80 per month, depending on coverage.
Historical Price Trends
- The initial launch price in 2019 was around $900 per month.
- Recent promotions, increased competition, and payer negotiations have led to a 5% annual decrease in net pricing.
Price Projection Models
Short-term (2023–2025)
- Due to increased competition from similar oral GLP-1 drugs (e.g., Novo Nordisk's oral semaglutide candidate) and pricing pressures, wholesale prices are projected to decline by an average of 3% annually.
- With expanded formulary access and increased adoption, the net effective price to the patient is expected to remain stable or decline slightly.
Mid-to-long term (2026–2030)
- Introduction of biosimilars and generic equivalents, though unlikely for semaglutide due to patent exclusivity until at least 2032.
- Market penetration could push the average cost to decline by up to 10% by 2030, provided demand sustains.
| Year |
Estimated Wholesale Price per 30-dose tablet |
Estimated Net Price (after discounts) |
| 2023 |
$820 |
$620 |
| 2025 |
$790 |
$595 |
| 2030 |
$720 |
$540 |
Note: These figures reflect assumptions of competitive pricing pressures, not accounting for potential market shifts such as supply chain disruptions or regulatory changes.
Regulatory and Policy Impact
- Medicaid and Medicare price negotiations could influence pricing beyond 2025.
- Policies favoring oral over injectable medications may increase demand, thus exerting upward pressure on prices in certain markets.
- Patent extensions or litigation outcomes could either delay entry of generics/biosimilars or prevent them, maintaining higher prices.
Key Market Drivers
- Increasing prevalence of type 2 diabetes: By 2030, approximately 537 million adults expected with the disease (International Diabetes Federation).
- Patient preference for oral medications: Drives uptake of Rybelsus over injectables.
- Payer and provider preferences: Favor oral drugs if efficacy and safety profiles are comparable.
Key Takeaways
- Rybelsus holds a significant position in the oral GLP-1 segment, with ongoing growth driven by diabetes prevalence and patient preferences.
- Current wholesale prices average around $820 for a 30-dose tablet, with real-world net prices approximately $620.
- Short-term pricing is likely to decline modestly due to competition and payer negotiations.
- Long-term price declines could reach 10% if biosimilar or generic equivalents gain approval or market entry.
- Market dynamics are susceptible to regulatory, patent, and policy changes, which could influence future pricing.
FAQs
1. Will Rybelsus’s price increase or decrease in the future?
Prices are expected to decline slightly through competition and policy pressures, though incremental increases could occur if demand outpaces supply or regulatory barriers hinder generic entry.
2. How does Rybelsus compare prices to injectable GLP-1 therapies?
Oral Rybelsus generally offers a lower annual cost compared to injectable options like Ozempic and Trulicity, partly due to differences in administration and formulation costs.
3. What factors could significantly alter pricing projections?
Introduction of biosimilars, patent litigation outcomes, changes in healthcare policy, and shifts in demand can impact prices substantially.
4. How does reimbursement influence the net price of Rybelsus?
Insurance negotiations, formulary placements, and patient copay structures determine the net price, often lowering effective costs by 15-25%.
5. What is the outlook for Rybelsus’s market share?
Market share is poised to grow modestly, potentially reaching 25% of the oral GLP-1 segment by 2030, assuming continued efficacy and favorable formulary positioning.
Sources
[1] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] U.S. Food and Drug Administration. (2019). Rybelsus (semaglutide) Label.
[4] EvaluatePharma. (2022). Global Market Data & Projections.
[5] Centers for Medicare & Medicaid Services. (2022). Drug Price Negotiation Policies.
